A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
This finding can help addicts cut on their dependency. Researchers believe that Ozempic and Wegovy, different brand names for ...
It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
The effects last only for a few hours. Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...
GLP-1s seem to be everywhere. The appetite suppressant drugs, with brand names like Ozempic and Wegovy, have grown in ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...